Computational Cognitive Training To Boost Reward Responsiveness In Anhedonic Patients

NCT ID: NCT05383248

Last Updated: 2023-11-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-14

Study Completion Date

2023-11-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Anhedonia, i.e., reduced positive mood and decreased sensitivity to rewards, is observed in many psychiatric illnesses, particularly depression and anxiety disorders. Untreated anhedonia predicts worse clinical outcomes and poorer response to treatment, yet cognitive behavioral treatment approaches to target anhedonia are fraught with poor patient compliance in real-life settings. The proposed study aims to address this gap by 1) testing the usefulness of a non-invasive, computationally informed, cognitive training in boosting reward sensitivity and reducing anhedonia in depressed and anxious patients, and 2) delineating the neurocomputational mechanisms of change associated with such intervention. In other words, can we train the brain to obtain rewards and boost positive mood among depressed and anxious individuals? This project will help to develop a computational training protocol aimed at reducing anhedonia and improving existing interventions for psychiatric conditions characterized by reward processing deficits. Long-term goals include expanding this framework to a broader range of appetitive and social stimuli to develop precise cognitive training tools to treat anhedonia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anhedonia Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

High Reward - High Variance

Group Type EXPERIMENTAL

High Reward - High Variance

Intervention Type BEHAVIORAL

Computerized reward learning task designed to increase reward responsiveness

High Reward - Low Variance

Group Type ACTIVE_COMPARATOR

High Reward - Low Variance

Intervention Type BEHAVIORAL

Computerized reward learning task designed to have minimal effect on reward responsiveness

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

High Reward - High Variance

Computerized reward learning task designed to increase reward responsiveness

Intervention Type BEHAVIORAL

High Reward - Low Variance

Computerized reward learning task designed to have minimal effect on reward responsiveness

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-65 (all races, both males and females will be included)
* Current diagnosis of Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD)
* A score \< 7 on the Snaith-Hamilton Pleasure Scale (SHAPS) or \< 25 on the Positive Affect subscale from the Positive And Negative Affect Scale (PANAS)
* Sufficient proficiency in English language to understand and complete informed consent, interviews, questionnaires, and all other study procedures.
* Having normal or corrected vision
* Having normal or corrected hearing

Exclusion Criteria

* Endorsement of past or current psychotic or bipolar disorder.
* Endorsement of recent severe alcohol or substance use disorder (past 3 months).
* Inability to discontinue for 48 hours prior to scan any medications incompatible with measuring reliable/interpretable neural activity (e.g., e.g., benzodiazepines/beta-blockers, atypical anti-depressants, anxiolytics and sedative hypnotics, antipsychotics, and opioid analgesics)
* Being unsafe to undergo functional magnetic resonance imaging (fMRI), i.e., being pregnant, presence of non-removable metal in body, medical conditions that are incompatible with safe MRI (e.g., claustrophobia, inability to lie still on one's back for approximately 60 minutes; prior neurosurgery)
* Clinical conditions assessed by the interviewer that necessitate more imminent clinical care (e.g., active suicidal ideation): These criteria are in place so participants with these other, more several symptoms can be referred for appropriate mental health services.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of California, San Diego

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Katia Harle

Assistant Clinical Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UCSD Center for Functional Magnetic Resonance Imaging

La Jolla, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

309646-00001

Identifier Type: -

Identifier Source: org_study_id